Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | MMP1 | P03956 | 2/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | MMP9 | P14780 | 2/20 | 0.33 |
| ▸ | MMP8 | P22894 | 2/20 | 0.33 |
| ▸ | MMP13 | P45452 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1006646 | 0.96 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL910572 | 0.96 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL1005294 | 0.96 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL330805 | 0.96 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL1007075 | 0.96 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL1007393 | 0.96 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL1006397 | 0.96 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL843600 | 0.96 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL1006453 | 0.96 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL1005703 | 0.96 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3763 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2867019-B1 | SLIDE BEARING COMPRISING A PRIMER SYSTEM AS ADHESION PROMOTER | SAINT GOBAIN PERFORMANCE PLASTICS PAMPUS GMBH (DE) | 2023-01-18 | — | — | EP | claimed |
| CN-112018441-B | Lithium secondary battery electrolyte, preparation method thereof and lithium secondary battery | 华为技术有限公司 | 2022-04-12 | — | — | CN | claimed |
| CN-107586370-B | Block polymer and random polymer for directed self-assembly, and preparation method and self-assembly method thereof | 北京科华微电子材料有限公司 | 2021-03-09 | — | — | CN | claimed |
| CN-112018441-A | Lithium secondary battery electrolyte, preparation method thereof and lithium secondary battery | 华为技术有限公司 | 2020-12-01 | — | — | CN | claimed |
| EP-2086924-B1 | [F-18]-LABELED L-GLUTAMIC ACID, [F-18]-LABELED L-GLUTAMINE, DERIVATIVES THEREOF AND USE THEREOF AND PROCESSES FOR THEIR PREPARATION | PIRAMAL IMAGING SA (CH) | 2018-09-12 | — | — | EP | claimed |
| US-9375497-B2 | [F-18]-labeled L-glutamic acid, [F-18]-labeled L-glutamine, derivatives thereof and use thereof and processes for their preparation | PIRAMAL IMAGING SA (CH) | 2016-06-28 | — | — | US | claimed |
| US-20140301948-A1 | [F-18]-LABELED L-GLUTAMIC ACID, [F-18]-LABELED L-GLUTAMINE, DERIVATIVES THEREOF AND USE THEREOF AND PROCESSES FOR THEIR PREPARATION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2014-10-09 | — | — | US | claimed |
| US-20100217011-A1 | [F-18]-LABELED L-GLUTAMIC ACID, [F-18]-LABELED L-GLUTAMINE, DERIVATIVES THEREOF AND USE THEREOF AND PROCESSES FOR THEIR PREPARATION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-26 | — | — | US | claimed |
| EP-2123619-A1 | New [F-18]-marked L-glutamic acids and L-glutamic acid derivatives (II), application thereof and method for their manufacture | Bayer Schering Pharma AG (DE) | 2009-11-25 | — | — | EP | claimed |
| EP-2123621-A1 | New [F-18]-marked L-glutamic acids and L-glutamic acid derivatives (1), application thereof and method for their manufacture | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-11-25 | — | — | EP | claimed |
| EP-1923382-A1 | [18F] labelled L-glutamic acid, [18F] labelled glutamine, their derivatives, their use and processes for their preparation | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-05-21 | — | — | EP | claimed |
| WO-2008052788-A1 | [F-18]-LABELED L-GLUTAMIC ACID, [F-18]-LABELED L-GLUTAMINE, DERIVATIVES THEREOF AND USE THEREOF AND PROCESSES FOR THEIR PREPARATION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-08 | — | — | WO | claimed |
| US-6713468-B2 | AS ANTICONVULSANTS; FOR THERAPY AND PROPHYLAXIS OF ISCHAEMIAS, ANOXIA, NEURODEGENERATIVE DISEASES | AVENTIS PHARMA S.A. (FR) | 2004-03-30 | — | — | US | claimed |
| US-20030055031-A1 | Methods of using thiazolobenzoheterocycles | RHONE-POULENC RORER S.A. | 2003-03-20 | — | — | US | claimed |
| US-6448241-B1 | THESE COMPOUNDS ARE ANTICONVULSANTS AND INTERFERE WITH GLUTAMATERGIC TRANSMISSION AND ARE THEREFORE USEFUL FOR THE TREATMENT OR PREVENTION OF ALL ISCHAEMIAS FOLLOWING CEREBROVASCULAR ACCIDENTS | AVENTIS PHARMA S.A. (FR) | 2002-09-10 | — | — | US | claimed |
| EP-0966473-B1 | THIAZOLOBENZOHETEROCYCLES, PREPARATION AND MEDICINES CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2002-07-24 | — | — | EP | claimed |
| US-6423715-B1 | ANTICONVULSANTS | AVENTIS PHARMA S.A. (FR) | 2002-07-23 | — | — | US | claimed |
| US-6288075-B1 | ANTIEPILEPTIC AGENTS; NERVOUS SYSTEM, BRAIN, AND CARDIOVASCULAR DISORDERS | RHONE-POULENC RORER S.A. (FR) | 2001-09-11 | — | — | US | claimed |
| EP-0966473-A1 | THIAZOLOBENZOHETEROCYCLES, PREPARATION AND MEDICINES CONTAINING SAME | Aventis Pharma S.A. (FR) | 1999-12-29 | — | — | EP | claimed |
| WO-1998038194-A1 | THIAZOLOBENZOHETEROCYCLES, PREPARATION AND MEDICINES CONTAINING SAME | RHONE-POULENC RORER S.A. (FR) | 1998-09-03 | — | — | WO | claimed |